For example, in the case of systemic lupus erythematosus (SLE), only an anti-B-cell activating factor (-BAFF) mAb has shown a moderate efficacy in some patients (27), whereas other indications like MS have not yet clearly benefited from targeted cytokine blockade. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.